C07K 14/70546
Integrin superfamily
Official title: {Integrin superfamily}
C07K14/70546 (Integrin superfamily) appears on 464 US grants and 853 published applications in this corpus.
Search patents in C07K- Granted patents
- 464
- Published applications
- 853
- Assignees
- 209
- Inventors
- 834
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 4 | 0 |
| 1993 | 6 | 0 |
| 1994 | 5 | 0 |
| 1995 | 10 | 0 |
| 1996 | 11 | 0 |
| 1997 | 17 | 0 |
| 1998 | 24 | 0 |
| 1999 | 14 | 0 |
| 2000 | 13 | 0 |
| 2001 | 11 | 2 |
| 2002 | 7 | 21 |
| 2003 | 9 | 439 |
| 2004 | 7 | 34 |
| 2005 | 5 | 30 |
| 2006 | 17 | 13 |
| 2007 | 72 | 14 |
| 2008 | 70 | 13 |
| 2009 | 14 | 16 |
| 2010 | 11 | 12 |
| 2011 | 9 | 15 |
| 2012 | 8 | 9 |
| 2013 | 8 | 8 |
| 2014 | 7 | 11 |
| 2015 | 9 | 12 |
| 2016 | 5 | 11 |
| 2017 | 7 | 15 |
| 2018 | 8 | 22 |
| 2019 | 10 | 15 |
| 2020 | 8 | 23 |
| 2021 | 11 | 25 |
| 2022 | 7 | 23 |
| 2023 | 17 | 23 |
| 2024 | 5 | 17 |
| 2025 | 8 | 16 |
| 2026 | 8 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation25 Aug 2026US 12,714,678 B2The Board of Trustees of the University of Illinois
- Integrin-targeting protein and methods of use thereof16 Jun 2026US 12,655,197 B2Georgia State University Research Foundation, Inc.
- Engineered muscle targeting compositions5 May 2026US 12,618,082 B2Massachusetts Institute of Technology
- Methods for treating drug resistant cancers14 Apr 2026US 12,601,743 B2The Regents of the University of California
- Integrin targeting ligands and uses thereof24 Mar 2026US 12,582,718 B2Arrowhead Pharmaceuticals, Inc.
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Engineered muscle targeting compositions27 Aug 2026US 2026/0250713 A1Massachusetts Institute of Technology
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies20 Aug 2026US 2026/0242801 A1ImmunityBio, Inc.
- Humanized anti-cd11b antibodies and methods of use thereof13 Aug 2026US 2026/0234267 A1Kaigene, Inc.
- Novel a4b7 thioether peptide dimer antagonists30 Jul 2026US 2026/0217767 A1Protagonist Therapeutics, Inc.
Most cited
By later US patents
- Vitronectin specific cell receptor derived from mammalian mesenchymal tissue221US 4,789,734 ALa Jolla Cancer Research Foundation · 1988
- Penton base protein and methods of using same136US 5,559,099 AGenVec, Inc. · 1996
- Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer84US 7,919,467 B2Immunotope, Inc. · 2011
- Polymorphism of human platelet membrane glycoprotein IIIa and diagnostic and therapeutic applications thereof77US 5,091,302 AThe Blood Center of Southeastern Wisconsin · 1992
- Methods and compositions useful for inhibition of angiogenesis77US 5,753,230 AThe Scripps Research Institute · 1998